JP-2266

JP-2266 is an orally administered, synthetic small molecule drug developed as a dual inhibitor of sodium/glucose cotransporter 1 (SGLT1) and sodium/glucose cotransporter 2 (SGLT2). Its mechanism of action involves inhibiting renal SGLT2 to promote urinary glucose excretion and intestinal SGLT1 to delay glucose absorption, thereby reducing postprandial blood glucose levels. JP-2266 is being investigated primarily for the treatment of type 2 diabetes mellitus, with additional research in type 1 diabetes mellitus as an adjunct or alternative to insulin therapy. The drug has demonstrated significant reductions in postprandial glucose and HbA1c in preclinical models and aims to offer improved glycemic control with a lower risk of hypoglycemia compared to conventional insulin injections. It is currently in phase 2 clinical development[1][2][3][5][6][8].

Other names

SGLT1/2 dual inhibitorSGLT1/SGLT2 dual inhibitor